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Epigenetic aberrations offer dynamic and reversible targets for cancer therapy; increas-
ingly, alteration via overexpression, mutation, or rearrangement is found in genes that
control the epigenome. Such alterations suggest a fundamental role in carcinogenesis.
Here, we consider three epigenetic mechanisms: DNA methylation, histone tail modifi-
cation and non-coding, microRNA regulation. Evidence for each of these in lung cancer
origin or progression has been gathered, along with evidence that epigenetic alterations
might be useful in early detection. DNA hypermethylation of tumor suppressor promoters
has been observed, along with global hypomethylation and hypoacetylation, suggesting
an important role for tumor suppressor gene silencing.These features have been linked as
prognostic markers with poor outcome in lung cancer. Several lines of evidence have also
suggested a role for miRNA in carcinogenesis and in outcome. Cigarette smoke downreg-
ulates miR-487b, which targets both RAS and MYC; RAS is also a target of miR-let-7, again
downregulated in lung cancer. Together the evidence implicates epigenetic aberration in
lung cancer and suggests that targeting these aberrations should be carefully explored.To
date, DNA methyltransferase and histone deacetylase inhibitors have had minimal clinical
activity. Explanations include the possibility that the agents are not sufficiently potent to
invoke epigenetic reversion to a more normal state; that insufficient time elapses in most
clinical trials to observe true epigenetic reversion; and that doses often used may provoke
off-target effects such as DNA damage that prevent epigenetic reversion. Combinations
of epigenetic therapies may address those problems. When epigenetic agents are used
in combination with chemotherapy or targeted therapy it is hoped that downstream bio-
logical effects will provoke synergistic cytotoxicity.This review evaluates the challenges of
exploiting the epigenome in the treatment of lung cancer.
Keywords: epigenetics, non-small cell lung cancer, small-cell lung cancer, DNA methylation, histone modification,
microRNA
INTRODUCTION
Lung cancer is the second most common cancer and leading cause
of cancer-related death in both males and females in the United
States (1). Traditionally, lung cancer histology allowed it to be
divided into two morphologic groups that also demonstrate dis-
tinct clinical features: non-small cell lung cancer (NSCLC), which
represents around 85% of all cases, and small-cell lung cancer
(SCLC). About 80–90% of NSCLCs are directly related to tobacco
smoke, while nearly all small cell lung cancers are associated with
smoking (2). The vast majority of lung cancers present as advanced
and incurable disease at the time of diagnosis (SEER Cancer
Statistics Review, 1975–2008); in these patients platinum-based
chemotherapy remains a standard treatment for the majority of
patients with NSCLC and SCLC, with overall survival (OS) less
than 12 months (3, 4). Tailoring chemotherapy according to his-
tologic subset has been shown to improve efficacy in patients with
NSCLC (5).
Further progress has been made more recently with improved
understanding of the molecular mechanisms involved in oncoge-
nesis (6). These advances enabled the development of drugs that
target cancer cell specific gene alterations. These targeted drugs sig-
nificantly improved response rates and progression-free survival
(PFS) in patients with specific genetic alterations (7–9). Despite
these advances, the prognosis of patients with both advanced
NSCLC and advanced SCLC, remains poor.
Gene expression is regulated by epigenetic mechanisms; epige-
netic alterations play important roles in many physiological and
pathophysiological conditions, including carcinogenesis, without
changes in DNA sequence (10). In addition to genetic alterations
in DNA sequence, cancers harbor numerous epigenetic alterations,
which regulate gene expression and signaling pathways in the
malignant cell. Moreover, these alterations can outnumber genetic
alterations and usually occur early in carcinogenesis (11). Numer-
ous data suggest that epigenetics together with genetics intersect
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to promote carcinogenesis at all stages of cancer development.
Increasingly, genomic sequencing of human tumors has identified
mutations in genes that encode proteins regulating the epigenome.
Epigenetic alterations are in many cases dynamic and reversible,
thus representing interesting targets for cancer therapy (12). This
review will focus on epigenetic mechanisms of gene regulation
in lung cancer and discuss the therapeutic implication of these
alterations.
TYPES OF EPIGENETIC CHANGES
Epigenetic mechanisms of gene expression involve various
reversible alterations in chromatin structure without changes in
nucleotide sequence. Chromatin is the macromolecular complex
of DNA and histone proteins that allows packing the entire genome
in a single cell. The basic functional unit of chromatin is the nucle-
osome, an octamer containing two each of the histones H2A, H2B,
H3, and H4, around which 146 bp of DNA are wrapped (13).
Consecutive nucleosomes are separated by linker DNA, usually
20 and 50 bp in length (14). Classically, nucleosomal DNA is less
accessible than linker DNA; the degree of compaction of nucleo-
somes strongly influences the ability of proteins to target sequences
within DNA, modulating transcription, repair, and replication of
genes. There are three main types of epigenetic mechanisms: DNA
methylation, histone tail modification and non-coding, micro
RNA regulation (15).
DNA METHYLATION
The longest studied epigenetic mechanism of gene expression reg-
ulation is the methylation of cytosine residues in CpG sites in
the 5′ region of genes. Both DNA hypomethylation and hyper-
methylation are commonly described in human cancer cells (10).
Hypermethylation generally leads to gene silencing and inactiva-
tion in tumor suppressor genes, whereas hypomethylation leads to
genomic instability and active transcription (15, 16). Global DNA
hypermethylation occurs early in the carcinogenesis of lung can-
cer. Liu et al. showed that hypomethylation of DNA repeats and
upregulation of imprinted alleles precede hypermethylation and
epigenetic silencing of tumor suppressor genes in epithelial cells
exposed to tobacco smoke (17). DNA methylation is mediated via
three DNA methyltransferases (DNMT): DNMT1 – 3a and 3b.
DNMT1 binds to hemimethylated DNA to maintain methylation
patterns after DNA replication (18). On the other hand, DNMTs 3a
and 3b bind to unmethylated or hemimethylated DNA to mediate
de novo DNA methylation (19). Pre-clinical studies have suggested
that aberrant expression of DNMTs is involved in carcinogenesis
of lung cancer via tumor suppressor gene silencing (20). For exam-
ple, DNMT1 and DNMT 3b overexpression in lung cancer cells has
been correlated with promotor hypermethylation and silencing of
the tumor suppressor gene p16 in lung cancer cells (21). Simulta-
neous overexpression of all three DNMTs and hypermethylation
of several tumors suppressor genes including p16, FHIT, and RAR-
β was reported by Lin and colleagues (22). Multiple reports have
suggested that epigenetic silencing of tumors suppressor genes is
involved in the initiation and progression of lung cancer (23–26).
MODIFICATION OF HISTONE TAILS
Lysine-rich tails of core histones (H2A, H2B, H3, and H4) protrude
from the nucleosome providing sites for reversible modifications
that alter chromatin structure and modulate gene expression (27).
These modifications include methylation, acetylation, phospho-
rylation, sumoylation, and ubiquitination – some of these mod-
ifications mark active and some inactive chromatin states (15).
The most extensively studied modifications are histone lysine
acetylation/deacetylation and methylation/demethylation (27).
Acetylation of histone tails is mediated by a number of histone
acetyltransferases (HAT) including GNAT, MYST, and p300 fami-
lies (27, 28). On the other hand, histone deacetylation is mediated
by the histone deacetylase enzymes (HDAC), which are classified
in four subfamilies (29). Histone acetylation leads to chromatin
relaxation and gene expression, whereas deacetylation leads to
gene silencing (30). Non-histone proteins also undergo changes
in acetylation state mediated by HATs and HDACs (31).
Numerous histone methyltransferases (KMT) mediate mono,
di-, or trimethylation of lysine residues (27). Histone lysine
demethylation, on the other hand, is mediated by histone
dimethyltransferases (KDMT) (32). Histone methylation may
either activate or inhibit gene transcription, depending on the site
of action. For example, methylation of lysine 4 on H3 (H3K4) is
strongly associated with transcription activation, whereas methy-
lation of lysine 27 on H3 is frequently associated with gene silenc-
ing (15). Like histone acetylation, many non-histone proteins such
as p53, E2F1, and NFB can be targets of KMT and KDMT (27).
Kim et al showed that increased activity of KMT DOT1L,
which mediates methylation of H3K79, supports carcinogene-
sis of lung cancer cells (33). It is thought that methylation at
K79 promotes/inhibits transcriptional elongation, thereby induc-
ing overexpression/underexpression of different cell cycle regula-
tory genes and different tumor suppressor genes such as HOXA9
and RASSF1A. Overexpression of JARID1B (KDM5B), which
demethylates H3K4Me3/Me2, has been observed in both NSCLC
and SCLC (34). This overexpression correlated with increased
expression of E2F1 and E2F2. Upregulation of LSD1 (KDM1A),
which catalyzes demethylation of H3K4Me2/Me1 and possibly
H3K9Me2/Me1, was observed in small cell lung cancers rela-
tive to normal lung tissues (35). Various alterations in methyla-
tion/demethylation and acetylation/deacetylation of core histone
in lung cancer cells can be involved in lung carcinogenesis. For
example, hyperacetylation of H4K5 and H4K8, hypoacetylation
of H4K12/H4K16, and decreased H4K20Me3 levels were observed
in lung cancer cells relative to adjacent normal respiratory epithe-
lia (36). It is important to note that these studies report on global
changes in expression of specific histone modifications. What is
missing is an understanding of which gene promoters are critically
affected by these modifications, and which ensuing gene expres-
sion changes are involved in carcinogenesis. It is not clear whether
changes in histone methylation or acetylation are oncogenic in
themselves, or more permissive in allowing the dysregulation of
cell growth that is a hallmark of cancer.
MicroRNAs
MicroRNAs (miRNAs) are small regulatory RNAs, approximately
22 nucleotides long, that control gene expression by binding to
the 3′ untranslated region of messenger RNA (mRNA), leading
to either mRNA degradation or inhibition of protein translation
(37). As negative regulatory factors, miRNAs have emerged as
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key post-transcriptional regulators of gene expression, involved
in many physiological and pathological processes, such as prolif-
eration, differentiation, death, and stress resistance, mediated by
altering levels of gene expression (16, 37). There are more than
1,000 mature miRNAs in the human genome according to the
miRBase (http://www.mirbase.org/) and it is expected that many
more miRNAs will be identified in the future, making their inter-
actions even more complex (15). A single miRNA can target many
different mRNAs, and a single mRNA can be targeted by multiple
miRNAs, thereby creating a complex network of molecular path-
ways in cells. Altered expression of miRNAs is commonly found in
cancer, and is thus thought to be associated with and potentially
contributing to the pathogenesis of most malignancies, including
lung cancer, with a miRNA having the potential to serve as either
oncogene or tumor suppressor gene, depending on its gene target
(38, 39).
The role of the let-7 miRNA family in lung carcinogenesis has
been extensively studied. One of the main targets of let-7 miRNA
is KRAS (40, 41), leading to its down-regulation. Johnson et al
showed that let-7 miRNA expression is lower in lung tumors than
in normal lung tissue, while RAS protein is significantly higher
in lung tumors, providing a possible mechanistic involvement of
let-7 miRNA in carcinogenesis in a subset of lung cancers (40).
Hayashita et al. observed that the polycistronic microRNA cluster,
miR-17-92, is overexpressed in human lung cancers and enhances
cell proliferation and tumor development (42). A recent study
demonstrated that loss of miR-365 might also be involved in lung
carcinogenesis via decreased suppression of NKX2-1, a transcrip-
tion factor also known as TTF-1 that is thought to be involved
in lung cancer carcinogenesis (43). Enforced NKX2-1 overex-
pression significantly increased cell proliferation, overcoming the
suppressive effect of miR-365 (43).
Xi et al. observed that cigarette smoke repressed miR-487b in
cultured respiratory epithelia and lung cancer cells (44). Subse-
quent experiments revealed significant repression of miR-487b
in primary lung cancers – particularly those from smokers, rela-
tive to adjacent normal lung tissues. Repression of miR-487b in
cultured cells following cigarette smoke exposure and in primary
lung cancers coincided with DNA methylation and recruitment of
polycomb repressor proteins to the miR-487b regulatory region.
Notably, miR-487b directly targets transcripts encoding the non-
canonical Wnt ligand, Wnt5a; polycomb repressor proteins BMI1
and SUZ12; and the oncogenes KRAS and MYC. Repression of
miR-487b correlated with overexpression of all five transcripts
in primary lung cancers. Collectively, these findings demonstrate
links between cigarette smoke and the epigenetic repression of
a microRNA regulating the expression of five genes involved in
oncogenesis.
PROGNOSTIC AND PREDICTIVE VALUE OF EPIGENETIC
CHANGES
Early detection of lung cancer could change disease outcome.
Until recently, there had not been a screening test that demon-
strated a mortality reduction in lung cancer. The National Lung
Cancer Screening Trial showed that screening high-risk persons
with low-dose CT scanning could significantly reduce lung can-
cer mortality (45). However, the expense and the potential for
harm from even low-dose radiation, raises the question of other
approaches. Epigenetic changes develop in smokers and early in
lung carcinogenesis, making them potential biomarkers for early
detection of lung cancer. Several early but interesting studies have
been reported utilizing sputum as a source of tumor cell DNA.
Unfortunately, these studies suffer from the problem of “searching
under the lamp-post.”As a result there are multiple different epige-
netic marks that have been associated with outcome of lung cancer
and no comparative analysis that would allow clinical investigators
to choose among them for validation studies.
Methylguanine-DNA methyltransferase is a DNA repair
enzyme that protects cells from the carcinogenic effects of alkylat-
ing agents by removing adducts from the O6 position of guanine;
MGMT is frequently inactivated by aberrant promoter methyla-
tion in NSCLC (46). Palmisano et al. demonstrated that aberrant
methylation of the promoters of the tumor suppressor genes p16
and/or O6-methylguanine-DNA methyltransferase (MGMT) can
be detected in DNA from sputum in 100% of patients with squa-
mous cell lung carcinoma up to 3 years before clinical diagnosis
(47). Another study confirmed that aberrant promoter hyperme-
thylation of the p16 gene, and to a lesser extent DAP kinase, is
detectable in sputum, occurs frequently in smokers and persists
after smoking cessation (48).
The melanoma antigen gene (MAGE) is a highly specific tumor
marker, and MAGE-A3 expression has been detected in 35% of
lung cancer samples and also in pre-cancerous lesions (49, 50).
Shin et al. collected sputum from 133 patients with lung dis-
eases (65 lung cancers and 68 benign lung diseases) and showed
methylation abnormalities in patients with MAGE-positive spu-
tum (in both malignant and benign diseases). Thus, MAGE expres-
sion in the sputum suggests the presence of lung cancer cells or
pre-cancerous cells (51).
Interestingly, sputum miRNA profiling using a cluster of five
miRNAs (miR-21, miR-143, miR-155, miR-210, and miR-372)
detected NSCLC (with 83.3% sensitivity and 100% specificity)
in 30 patients. If validated in larger, prospective studies, sputum
miRNA profiling could represent a potentially valuable approach
for the early detection of NSCLC (52).
PROGNOSTIC MARKERS
Epigenetic changes have been linked to early recurrence in resected
NSCLC. Brock and colleagues reported that DNA methylation in
the promoter region of four genes (TP16, CDH13, RASSFIA, and
APC) was associated with early recurrence in patients with resected
stage I NSCLC (53). Barlési et al. classified 138 lung cancer patients
into seven groups based on histology, stage, and global expression
levels of H3K4Me2, H2AK5Ac, and H3K9Ac. The groups showed
significant differences in disease-free and OS. High intratumoral
levels of H3K4Me2 showed significant improvement in OS com-
pared to patients with high intratumoral levels of H3K9Ac (147 vs.
10 months) (54). These changes may help in selecting early-stage
NSCLC patients for adjuvant treatment.
DNMT1 accumulation and subsequent hypermethylation of
the promoter of tumor suppressor genes may lead to tumorigen-
esis and provide an important link between tobacco smoking and
lung cancer (55). Xing et al. examined DMNT1 and DNMT3b,
as well as methylated DNA-binding protein 2 (MBD2) expression
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in 148 resected NSCLC samples. High DNMT1 expression cor-
related significantly with increased risk of cancer-related death
in all patients, whereas increased DNMT3b expression was asso-
ciated with poor outcome in patients less than 65 years of age.
High-level expression of MBD2 correlated with poor survival in
male patients and those with squamous cell carcinomas (56). The
previously mentioned study conducted by Kim and colleagues
demonstrated that overexpression of DNMT1 is correlated with
p16 promoter hypermethylation and diminished patient survival
(21). High intranuclear DNMT1 levels correlated significantly
with smoking status and poor survival in 124 patients with lung
cancer (55). Importantly, DNMT1 overexpression in lung cancer
patients who smoked continuously correlated with poor progno-
sis. The key genes beyond p16 that are hypermethylated and lead
to a poor prognosis in patients diagnosed with lung cancer are not
known.
Increased HDAC1 mRNA levels appear to be more common in
advanced stages of disease in lung cancer patients, thus suggesting
a role of HDAC in more aggressive tumors (57). Minamyia et al
demonstrated that lung cancer patients with high intratumor lev-
els of HDAC3 had significantly shorter disease-free survivals than
patients whose tumors exhibited low HDAC3 expression. They
also stated that HDAC3 overexpression was an independent prog-
nostic factor for poor survival in patients with adenocarcinomas,
but not in those with squamous cell carcinomas (58). Given that 94
patients were included in this retrospective analysis, confirmatory
studies of the role of HDAC3 in NSCLC are needed.
Cellular levels of both H3K4me2 and H3K18ac were reported
to predict clinical outcome in lung cancer patients, with lower
levels predicting significantly poorer survival (59). Lower global
levels of histone modifications are generally predictive of a more
aggressive cancer phenotype, revealing a surprising commonality
in prognostic epigenetic patterns of adenocarcinomas of different
tissue origins, including lung cancer (59).
In a study that analyzed NSCLC and neighboring normal lung
tissues, high levels of miR-155 and low miR-let-7a-2 expression
were found to correlate with poor survival in lung adenocarci-
nomas (39). In another study, low let-7 miRNA expression was
also significantly associated with shorter survival in 143 resected
lung cancer patients (60). Further attempts in addition to sputum
analysis, have attempted to find valid biomarkers to detect lung
cancer. Interestingly, three separate studies reported that miR-21
overexpression correlated with the aggressiveness of the disease
and high levels of miR-21 in serum or plasma were strongly asso-
ciated with lymph node metastasis, advanced clinical stage, and
poor survival in patients with NSCLC (61–63).
PREDICTIVE MARKERS
A predictive marker is one that may aid in choice among ther-
apeutic options; there are only limited data for predictive epige-
netic aberrations in lung cancer patients. Molecular mechanisms
of drug resistance are not completely understood and believed
to be multifactorial, involving host factors, numerous molecu-
lar events, and genetic and epigenetic changes (64). In addition,
chemotherapeutics induce epigenetic changes in the promoter
area of specific genes, altering expression and possibly under-
lying resistance in many tumor types (65). One possible reason
for the development of chemoresistance in NSCLC might be the
epigenetic inactivation of certain tumor suppressor genes as a con-
sequence of chemotherapy treatment (66). Ibanez de Caceres and
colleagues reported that a loss of insulin-like growth factor binding
protein-3 (IGFBP-3) expression, mediated by promoter hyper-
methylation, resulted in a reduction of tumor cell sensitivity to
cisplatin in NSCLC. Authors suggested that basal methylation sta-
tus of IGFBP-3 before treatment may be a clinical biomarker and
a predictor of chemotherapy outcome, helping to identify patients
who are most likely to benefit from platinum-based chemother-
apy therapy alone or in combination with epigenetic treatment
(66). Expression levels of a miRNA described above as associated
with poor outcome, miR-21, were evaluated in tumor tissue and
plasma by Gao et al. in 58 patients with resected NSCLC (67).
The investigators found increased levels of miR-21 expression in
patients with chemotherapy-resistant NSCLC, and concluded that
miR-21 may be useful as a biomarker to predict adjuvant platinum-
based chemotherapy response and disease-free survival in patients
with NSCLC. Thus, it may serve as a novel therapeutic target to
modulate platinum-based chemotherapy.
TARGETING THE EPIGENOME
Unlike oncogenic mutations, which are fixed, epigenetic alter-
ations are potentially reversible. The reversibility of epigenetic
alterations provides the foundation for targeting them therapeu-
tically. To date, histone deacetylation and DNA methylation have
been successfully targeted in the clinic. Several epigenetic modi-
fiers have received FDA approval: DNMT inhibitors, decitabine,
and 5-azacitidine are approved for treatment of myelodysplas-
tic syndromes (68, 69) and HDAC inhibitors romidepsin and
vorinostat are approved for T-cell lymphoma (70–72).
The adverse effect profiles of these epigenetic drugs are well
known from their use for these approved indications. Peripheral
cytopenias are among the most common adverse effects of DNMT
inhibitors whereas gastrointestinal adverse effects and injection-
site reactions are among the most common non-hematological
adverse effects. The major adverse effects of HDAC inhibitors are
fatigue, nausea, and vomiting. Most of the agents cause thrombo-
cytopenia, lymphopenia, neutropenia, and electrocardiographic
changes including ST and T wave flattening and QT prolongation
(72, 73). Selective HDAC inhibition may provide greater efficacy
and a wider therapeutic window by reducing adverse effects.
EPIGENETIC THERAPY IN NSCLC
Table 1 shows the main classes of epigenetic therapies in lung
cancer. Table 2 summarizes clinical trials of epigenetic therapies
in lung cancer (74–87). Unlike hematological malignancies and
CTCL, monotherapy with epigenetic therapies have not proven
particularly efficacious in lung cancer, although in vitro both
romidepsin and vorinostat alone induce apoptosis in NSCLC and
SCLC (Figure 1). Available pre-clinical and clinical data suggests
that most HDAC inhibitors will be optimally used in combina-
tion: with chemotherapies, targeted therapies, radiation, or other
epigenetic modifiers, rather than as single agents (88–94).
COMBINATION WITH CHEMOTHERAPY AND RADIATION
Combinations with chemotherapy or radiation therapy and epi-
genetic agents have been based on the rationale that alterations
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Table 1 | Selected epigenetic drugs which are undergoing clinical evaluation in lung cancer.
Group Class Drug Mechanism of action
HDAC inhibitors Aliphatic acids Valproic acid Binds to catalytic pocket of lysine deacetylases, complexes with Zn2+ via
its carboxyl group and inhibits their activity
Hydroxamic acids Vorinostat Pan-HDAC inhibitor
Belinostat Pan-HDAC inhibitor
Panobinostat Pan-HDAC inhibitor
Benzamides Entinostat Inhibits only the class I enzymes HDAC1 to HDAC3
Cyclic peptides Romidepsin Prodrug whose disulfide bond must be reduced to yield the active form;
Inhibitor of class I HDACs
DNA methyl
transferase inhibitors
Nucleoside analogs Decitabine Phosphorylated form is incorporated in to DNA and inhibits DNA
methyltransferase 1
Azacytidine Inhibits DNA methyltransferase’s ability to transfer methyl groups to
hemimethylated DNA strands
Small molecules Hydralazine Partial competitive inhibitors of DNMT1, decreasing the affinity of DNMT
for its substrates
in gene expression induced by the epigenetic agent may allow
increased sensitivity and reverse resistance to treatment. For exam-
ple, increased topoisomerase II gene expression following HDAC
inhibition may increase sensitivity to etoposide (94). Alternately,
increased accessibility of DNA due to the “relaxed chromatin”
following HDAC inhibition may result in increased platinum
binding and increased efficacy. In yet another hypothesis, altered
chromatin states resulting from epigenetic alterations have also
been identified in small populations of cells that acquire a drug-
tolerant phenotype (95). This drug-tolerant subpopulation may
be selectively ablated by epigenetic therapies.
Early clinical observations in NSCLC have not supported the
pre-clinical findings of synergy between chemotherapy and epige-
netic therapy. A randomized placebo-controlled phase II trial of
previously untreated NSCLC patients showed improved response
rates when vorinostat was added to first-line carboplatin and pacli-
taxel (34% with vorinostat vs. 12.5% with placebo; P = 0.02) (82).
However, a phase III randomized trial was prematurely terminated
because of no anticipated improvement in response rates, PFS, or
OS (96).
These early failures at combining epigenetic therapy with con-
ventional DNA damaging agents may relate to a lack of under-
standing of the mechanisms underlying the in vitro synergy and the
conflicting data regarding the optimal schedule for the combina-
tion. Whereas some studies suggest that pretreatment with HDAC
inhibitors sensitizes cancer cells to chemotherapeutic agents, pre-
sumably because sequential treatment may facilitate access to DNA
(88–90, 92, 94); other studies are not in agreement with this obser-
vation (97, 98). We found that in SCLC cell lines, simultaneous
but not sequential treatment with HDAC inhibitors enhanced
double-stranded DNA breaks by cisplatin and etoposide. In fact,
pretreatment with HDAC inhibitors mitigated the cytotoxicity of
DNA damaging agents without increasing their access to DNA
(93).
Histone deacetylase enzymes inhibitors have been shown to
sensitize NSCLC to the cytotoxic effects of radiation through per-
sistence of DNA double-strand breaks and apoptotic cell death
both in vitro and in vivo (99). The enhanced cytotoxic effects of
radiation co-administered with HDAC inhibitors are thought to
be due to the effects of HDAC inhibitors decreasing expression or
function (via acetylation) of DNA repair proteins (100). Although
in theory, HDAC inhibitor induced tumor cell cycle arrest could
provide an efficient period for an enhanced response to radiation-
induced cell injury, many tumor cells lack the ability to arrest in
G1 and by that means to repair their DNA.
COMBINATION WITH TARGETED THERAPY
Epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKI), erlotinib, and gefitinib are standard treatments
for NSCLC and have striking activity against tumors with EGFR
mutations (101). However, resistance to the EGFR TKI is observed,
and often correlates with markers of epithelial-mesenchymal tran-
sition status. Higher levels of E-cadherin, an epithelial marker,
indicate sensitivity, whereas higher levels of vimentin and ZEB-1,
both mesenchymal markers, indicate resistance. Pre-clinical evi-
dence suggests that HDAC inhibitors can delay as well as reverse
EGFR-TKI resistance by inhibiting epigenetic modifications lead-
ing to drug tolerance as well as reverting the EMT phenotype
(102, 103). A BIM (BCL2L11) deletion polymorphism that results
in the generation of alternatively spliced isoforms of BIM that
lack the crucial BH3 domain and confers an EGFR TKI resis-
tant phenotype in NSCLC cell lines (104) can be epigenetically
restored restored by HDAC inhibition. BIM function is required
for apoptosis induction by EGFR-TKIs in EGFR mutant NSCLC
(105).
A randomized phase II study that evaluated erlotinib with and
without entinostat in previously treated patients with advanced
NSCLC and no prior EGFR-TKIs did not find any difference
in the primary end-point, 4 month PFS rate between the two
groups (Table 2) (102). However, in the subset of patients
with high E-cadherin levels, OS was longer in the patients who
received erlotinib with entinostat (9.4 vs. 5.4 months; hazard
ratio, 0.35; 95% CI, 0.13–0.92; P = 0.03). Interim results of a
phase I/II study of concurrent administration of vorinostat and
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Table 2 | Selected clinical trials of epigenetic therapies in lung cancer.
Drug Patients Study
design
Enrollment Drug administration ORR
(%)
Median
PFS (m)
Median
OS (m)
Author
year
MONOTHERAPY
Pivanex Advanced NSCLC
after prior treatment
Single arm
phase II
47 2.34 g/m2/day 6 h
CIVI×3 days q 21 days
6.4% 1.5 6.2 Reid et al.
(78)
CI-994 Advanced NSCLC
after prior treatment
Single arm
phase II
32 8 mg/m2 orally daily 7% NA 7.5 Wozniak et
al. (76)
Vorinostat Advanced NSCLC
after prior treatment
Single arm
phase II
16 400 mg orally daily 0 2.3 7.1 Traynor et
al. (80)
Panobinostat SCLC after 1–2 prior
treatments
Single arm
phase II
21 20 mg/m2 iv on day 1 and 8
every 21 days
10%d NR NR De Marinis
et al. (81)
Decitabine Advanced NSCLC
after prior treatment
Phase I/II 15 200–660 mg/m2 IV over 8 h
every 21 days
0 NR 6.7 Momparler
et al. (75)
Decitabine Advanced NSCLC
after prior treatment
Phase I 35 60–75 mg/m2/72 h CIV 0 NR NR Schrump
et al. (122)
Fazarabine Advanced NSCLC
after prior treatment
Single arm
phase II
23 72 h continuous infusion at
2 mg/m2/h every 21 days
0 8 NR Williamson
et al. (74)
Romidepsin Recurrent
platinum-sensitive
SCLC
Single arm
phase II
16 13 mg/m2 weekly IV
infusions for 3 of 4 weeks
0 1.8 6 Luchenko
et al. (93);
Otterson
et al. (116)
Romidepsin Recurrent lung cancer Single arm
phase II
19e 17.8 mg/m2 IV infusions on
days 1 and 7 of a 21-day cycle
0 NR NR Schrump
et al. (79)
COMBINATION WITH CHEMOTHERAPY
Pivanex+docetaxel
vs. docetaxel
Advanced NSCLC
after prior treatment
Randomized
phase II
225 P, 2.5 g/m2/day 6 h
CIVI×3 days, D, 75 mg/m
2 day 4
NRa NR NR Press
releasef
Gemcitabine+C1-
994 or
placebo
Advanced NSCLC
after prior treatment
Randomized
placebo-
controlled
phase II
180 NA 3.5 vs.
3.8%
NA 6.3 vs.
6.2
Von Pawel
et al. (77)
Carboplatin+
paclitaxel+
Vorinostat or
placebo
Advanced NSCLC with
no prior treatment
Randomized
placebo-
controlled
phase II
94 V, 400 mg daily or placebo on
days 1–14 CP every 3 weeks
34 vs.
12.5%b
6 vs.
4.1
13 vs.
9.7
Ramalingam
et al. (82)
COMBINATION WITHTARGETEDTHERAPIES
Erlotinib+Entinostat
or placeboc
Advanced NSCLC
with 1–2 prior
chemotherapy
Randomized
placebo-
controlled
phase II
132 E, 150 mg orally daily for
28 days+ En, 10 mg orally
daily on days 1–15 vs. E+Pl
3 vs.
9.2%
1.9 vs.
1.8
8.9 vs.
6.7
Witta et al.
(102)
Bortezomib+
Vorinostat
Advanced NSCLC
with two prior
chemotherapy
Phase II 18 V, 400 mg orally daily on days
1–14+B, 1.3 mg/m2 IV D1, 4,
8, and 11 every 21 days
0 1.43 4.7 Jones et
al. (84)
Erlotinib+Vorinostat Advanced NSCLC
with EGFR mutations,
progression on
erlotinib
Phase I/II 24 E, 150 mg orally daily+V
400 mg orally daily on days
1-7 and 15-21
0 2 10.2 Cardenal
et al. (83)
(Continued)
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Table 2 | Continued
Drug Patients Study
design
Enrollment Drug administration ORR
(%)
Median
PFS (m)
Median
OS (m)
Author
year
COMBINATION OF EPIGENETICTHERAPIES
Decitabine+
Valproic acid
Advanced NSCLC
with up to two prior
therapy
Phase I 8 De (5–15 mg/m2)
IV×10 days+Val
(10–20 mg/kg/day) orally on
days 5–21 of a 28-day cycle
0 NR NR Chu et al.
(87)
Azacitidine+
Entinostat
Advanced NSCLC
after prior treatment
Phase I/II 45 A, 40 mg/m2 subcutaneous
on days 1–6, 8–10 En, 7 mg
orally on days 3, 10 of 28 day
cycle
4% 1.9 6.4 Juergens
et al. (85)
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; P, Pivanex; D, Docetaxel; V, Vorinostat; CP, Carboplatin/Paclitaxel; E, Erlotinib; En, Entinostat; Pl,
Placebo; B, Bortezomib; De, Decitabine; Val, Valproic acid; IV, intravenously; CIVI, continuous intravenous infusion; NR, not reported; NA, not available.
aStudy halted due to toxicities; development of the agent discontinued.
bSignificantly improved ORR in favor of vorinostat arm (P=0.02).
cPrimary end-point, 4 month PFS rate which was not significantly different between the groups (Erlotinib+Entinostat, 18% vs. Erlotinib+Placebo, 20%; P= 0.7).
dBoth responses were not confirmed on follow-up scans.
eIncludes 16 NSCLC and 3 NSCLC.
fhttp:// www.sec.gov/ Archives/ edgar/ data/ 910267/ 000101968704001384/ titan_8kex99-1.htm
FIGURE 1 | Lung carcinoma cells treated with HDAC inhibitors. Dose
response studies of cell cycle following 24 h treatment with either
romidepsin (DEPSI) or vorinostat (SAHA) are show in the histograms.
Concentrations are shown in the legend and represent equipotent
concentrations for growth inhibition (Luchenko et al., manuscript in
preparation). The NSCLC cell line responds to the HDAC inhibitor with G2
arrest and loss of the G1 peak, while the SCLC line H526 responds with
both G1 and G2 arrests and apoptosis.
erlotinib in patients with advanced NSCLC with EGFR muta-
tions who had prior disease progression on erlotinib showed
no objective responses (83). Whether the subset analysis of
the erlotinib/entinostat study will be sufficient to move the
combination forward with a selection strategy to enroll patients
with evidence of EMT in their tumors remains to be determined.
Given the in vitro evidence we would view the ability to revert
EMT as an important question to resolve.
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Many kinases, such as EGFR, rely on heat shock protein 90
(Hsp90) chaperone function for conformational maturation and
function. HDAC6 deacetylates Hsp90; HDAC6 inhibition results
in Hsp90 acetylation, which impairs its chaperone function. This
leads to degradation of client proteins. In NSCLC cell lines, HDAC
inhibition leads to Hsp90 acetylation, depletion of EGFR, and
other key survival signaling proteins, and triggers apoptosis only
in lung cancer cells harboring EGFR mutations (103). This mecha-
nism should also provoke synergy with EGFR inhibitors by reduc-
ing the level of mutant EGFR that requires inhibition. As noted
above, to date few clinical trials have explored this mechanism of
synergy, and most unsuccessfully.
Synergistic anti-proliferative effects were seen in pre-clinical
models with histone acetylation and proteasome inhibition.
HDAC6, a cytoplasmic, microtubule-associated member of the
class II family of HDACs plays an essential role in aggresomal
protein degradation, a pathway that is upregulated in the setting
of proteasome inhibition. Cells that lack HDAC6 do not form
aggresomes properly and fail to clear misfolded protein aggregates,
which by themselves are toxic (106). HDAC6 inhibition causes
the same failure of protein aggregates to traffic to the aggresome.
In some cell types, inhibition of proteasome-dependent path-
ways with bortezomib and the aggresome pathway with HDAC
inhibitors leads to a greater accumulation of polyubiquitinated
proteins with a resultant increase in cell stress and apoptosis (107).
Despite a strong pre-clinical rationale, a phase II study of borte-
zomib and vorinostat showed no evidence of clinical activity in
NSCLC (84).
COMBINATIONS OF EPIGENETIC MODIFIERS
DNA methyltransferases inhibitors and HDAC inhibitors in com-
bination have shown synergistic growth inhibition in NSCLC cell
lines (108, 109). Clinical studies in patients with hematologic
malignancies suggest that sequential administration of DNMT
inhibitors and HDAC inhibitors may reverse the silencing of a sub-
set of tumor suppressor genes by a combination of CpG hyperme-
thylation and histone hypoacetylation (110). Initial clinical studies
in NSCLC suggest that such combinations may increase clinical
efficacy without unacceptable toxicity. A phase I/II trial combined
azacitidine and entinostat, in patients with metastatic NSCLC
(n= 45) (85). One patient had a complete response that lasted
14 months. A second patient had a partial response that lasted
8 months. In the intent-to-treat population, the median PFS was
7.4 weeks (95% CI, 7.0–8.0 weeks) and median OS was 6.4 months
(95% CI, 3.8–9.2 months). Median survival among patients who
completed at least one cycle of epigenetic therapy was 8.6 months
(95% CI, 5.5–12.2 months). One observation in the post-study
follow-up of these patients was a major objective response in four
out of the 19 patients who received subsequent chemotherapy
(21%), which the authors suggested could indicate stable changes
in gene expression resulting from epigenetic therapy that altered
the cancer cell sensitivity to subsequent cytotoxic therapy.
EPIGENETIC THERAPY IN SCLC
Unlike NSCLC, there is a paucity of data on therapeutic targeting
of epigenetic alterations in SCLC. In pre-clinical in vitro stud-
ies, SCLC has proven sensitive to a number of HDAC inhibitors
including panobinostat (111), romidepsin (112), trichostatin
(113), and valproic acid (114, 115). Proposed mechanisms of activ-
ity of HDAC inhibitors in SCLC include activation of caspases,
down-regulation of antiapoptotic factors such as Bcl-2 and Bcl-
XL, and upregulation of p21 (111). However, three phase II studies
involving monotherapy with two HDAC inhibitors, panobinostat
and romidepsin, yielded no objective tumor responses (79, 81,
116).
Several pre-clinical studies of SCLC have shown additive effects
of combining epigenetic therapy with chemotherapy (111, 117),
and other epigenetic modifiers (118, 119) as well as noting the
importance of sequence of administration (93). In an ongoing
phase I study, we are evaluating the safety of the combination of
belinostat with cisplatin and etoposide in SCLC (NCT00926640).
Histone acetylation in peripheral blood mononuclear cells will
be determined following belinostat exposure to determine the
duration of sustained global acetylation.
CHALLENGES AND FUTURE DIRECTIONS
Clinical application of epigenetic therapies in lung cancer, and
in other tumor types, is still in its early days. Other epigenetic
targets such as histone methylation and miRNAs are still in pre-
clinical evaluation. There is more to learn about the mechanisms
most critical for cancer cell death caused by epigenetic drugs: what
are the genes that when demethylated and reexpressed, result in
differentiation or cell death? HDAC inhibitors cause global epi-
genetic changes and some, as we have alluded to above, may act
in opposition to promotion of cell death. Further, in lung cancer
cell lines and animal models, HDAC inhibition has been shown to
enhance cell migration and metastasis through induction of mul-
tiple protein kinases and downstream pathways (120). This may
diminish therapeutic efficacy, leading to unfavorable outcomes.
There is also a lack of understanding of resistance to epigenetic
drugs in lung cancer. Although in vitro studies have suggested sev-
eral mechanisms of resistance, they do not typically reflect the
insensitivity of solid tumors in the clinic (121). The dual goals
of overcoming resistance and the inherent potential of epigenetic
drugs to reactivate tumor suppressor genes, point toward the need
for rational drug combinations. Although early clinical evidence
suggests efficacy of combination therapies in NSCLC, the optimal
combinations, sequence, and doses need further study.
The experience with epigenetic drugs in the hematological
malignancy setting and the limited experience with solid tumors
suggest a delayed response to treatment possibly due to delay
between epigenetic effects and ensuing differentiation and cyto-
toxic effects. For example, the two responses to combination
epigenetic therapy in the phase I/II trial that combined azaci-
tidine and entinostat were gradual and maximal response was
achieved after only 6–8 months (81). Schrump et al. observed
progressive increases in NY-ESO-1 and MAGE-A3 expression in
sequential biopsies of an endobronchial tumor from a lung cancer
patient treated with Decitabine over a 12-month period (122). NY-
ESO-1 and MAGE-A3 protein expression in these biopsies, and
serum antibodies recognizing these cancer-testis antigens, were
detectable on and after the 6-month timepoint. These as well as
other observations from that trial provide molecular evidence
that prolonged exposures are necessary to mediate epigenetic
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alterations in lung cancer cells by DNA demethylating agents.
Thus, the conventional strategy of testing drugs in the advanced
setting may preclude detection of any clinical benefit from epige-
netic drugs in a rapidly growing tumor such as lung cancer. Such
delayed benefits may be best detected in the adjuvant setting; a ran-
domized phase II trial comparing 3 year PFS following adjuvant
combined epigenetic therapy with azacytidine and entinostat vs.
standard care in resected stage I NSCLC (NCT01207726) recently
closed. It can also be argued that effectiveness of epigenetic therapy
will depend upon its ability to revert the abnormal cancer-related
epigenetic changes rather than on direct or indirect cytotoxicity.
Hence, the traditional strategy of finding the highest dose that is
deemed safe, i.e., the maximum tolerated dose, may not necessarily
identify the dose with optimal biological effect. Lastly, identifica-
tion of lung cancer specific predictive biomarkers is important to
identify the appropriate subgroup that may respond to treatment.
As noted earlier, multiple biomarkers have been identified and
need further evaluation.
Emerging data from large-scale sequencing studies underscore
the major role of epigenetics in human cancer and point to a
much closer collaboration between genetic and epigenetic events
in carcinogenesis (123). Coupled with results of ongoing efforts
to map human epigenomes in great detail, this understanding will
significantly expand the implications of epigenome in lung cancer
detection, prevention, and treatment.
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